Azathioprine-induced severe cholestatic hepatitis in patient carrying TPMT*3C polymorphism

Pharm World Sci. 2010 Dec;32(6):701-3. doi: 10.1007/s11096-010-9443-4. Epub 2010 Oct 23.

Abstract

Case description: A 40-year-old man with pemphigus foliaceus developed a jaundice and pruritus three weeks after starting azathioprine 100 mg daily. Laboratory investigations revealed a severe cholestatic hepatitis. Azathioprine-induced hepatitis was suspected. The dosage of thiopurine methyltransferase activity showed a low activity of the enzyme and the genotype of this enzyme found a TPMT*3C heterozygous mutant allele. Azathioprine was withdrawn. The icterus regressed progressively and the hepatic tests normalised slowly. The patient had no further episodes of hepatitis over a follow-up period of 6 months.

Conclusion: Although, hematotoxicity seems to be associated with homozygous TPMT variants, a possible association between azathioprine hepatotoxicity and a TPMT*3C genotype should be investigated further.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Azathioprine / adverse effects*
  • Cholestasis, Intrahepatic / chemically induced
  • Cholestasis, Intrahepatic / enzymology*
  • Cholestasis, Intrahepatic / genetics*
  • Follow-Up Studies
  • Genetic Carrier Screening / methods
  • Heterozygote*
  • Humans
  • Male
  • Methyltransferases / genetics*
  • Polymorphism, Genetic / genetics*
  • Severity of Illness Index

Substances

  • Methyltransferases
  • thiopurine methyltransferase
  • Azathioprine